Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching Atripla to Eviplera for neurocognitive and emotional functioning in HIV
2014-004297-42Phase 4Active
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate and tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Neurocognitive performance after 12 weeks. Started Mar 2015; status: active.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumaratetenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2014-004297-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004297-42.